United-Guardian, Inc. (NASDAQ:UG) Given Consensus Rating of “Hold” by Brokerages

Share on StockTwits

United-Guardian, Inc. (NASDAQ:UG) has been given a consensus recommendation of “Hold” by the eleven brokerages that are presently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $26.95.

Several equities analysts have commented on the stock. Goldman Sachs Group reiterated a “buy” rating and issued a $26.00 price target on shares of United-Guardian in a research note on Wednesday, October 23rd. Nord/LB reiterated a “sell” rating and issued a $22.00 price target on shares of United-Guardian in a research note on Wednesday, October 30th. Jefferies Financial Group reiterated a “buy” rating and issued a $28.00 price target on shares of United-Guardian in a research note on Wednesday, October 30th. JPMorgan Chase & Co. reiterated a “buy” rating and issued a $36.00 price target on shares of United-Guardian in a research note on Wednesday, October 23rd. Finally, Sanford C. Bernstein reiterated a “buy” rating and issued a $30.00 price target on shares of United-Guardian in a research note on Wednesday, October 23rd.

Shares of United-Guardian stock opened at $18.91 on Monday. The firm has a market capitalization of $89.31 million, a P/E ratio of 22.60 and a beta of -0.29. United-Guardian has a 52 week low of $16.54 and a 52 week high of $20.81. The firm’s 50 day moving average is $18.79 and its two-hundred day moving average is $19.25.

United-Guardian (NASDAQ:UG) last announced its quarterly earnings results on Friday, November 8th. The company reported $0.23 EPS for the quarter. The company had revenue of $3.32 million for the quarter. United-Guardian had a net margin of 31.01% and a return on equity of 34.74%.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Morgan Stanley lifted its position in United-Guardian by 216.1% during the 2nd quarter. Morgan Stanley now owns 9,707 shares of the company’s stock worth $182,000 after acquiring an additional 6,636 shares in the last quarter. BlackRock Inc. lifted its position in United-Guardian by 8.7% during the 2nd quarter. BlackRock Inc. now owns 25,397 shares of the company’s stock worth $478,000 after acquiring an additional 2,039 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in United-Guardian by 2.3% during the 2nd quarter. Renaissance Technologies LLC now owns 262,800 shares of the company’s stock worth $4,941,000 after acquiring an additional 5,800 shares in the last quarter. 26.10% of the stock is currently owned by institutional investors and hedge funds.

About United-Guardian

United-Guardian, Inc manufactures and markets cosmetic ingredients, personal care products, pharmaceuticals, medical lubricants, healthcare products, and specialty industrial products in the United States and internationally. It offers personal care products, including LUBRAJEL line of water-based moisturizing and lubricating gel formulations; LUBRAJEL II XD; ORCHID COMPLEX, an oil-soluble base for skin creams, lotions, cleansers, and other cosmetics; LUBRASLIDE and B-122 powdered lubricants for use in the manufacture of pressed powders, eyeliners, and rouges; KLENSOFT, a surfactant for use in shampoos, shower gels, makeup removers, and other cosmetic formulations; and LUBRASIL, a special form of LUBRAJEL in which silicone oil is incorporated into a LUBRAJEL base.

See Also: How to Invest in Growth Stocks

Analyst Recommendations for United-Guardian (NASDAQ:UG)

Receive News & Ratings for United-Guardian Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United-Guardian and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.